Last reviewed · How we verify

Apremilast Modified Release 13 — Competitive Intelligence Brief

Apremilast Modified Release 13 (Apremilast Modified Release 13) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE4 inhibitor. Area: Immunology.

phase 1 PDE4 inhibitor PDE4 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Apremilast Modified Release 13 (Apremilast Modified Release 13) — Amgen. Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Apremilast Modified Release 13 TARGET Apremilast Modified Release 13 Amgen phase 1 PDE4 inhibitor PDE4
Otezla APREMILAST Amgen marketed Phosphodiesterase 4 Inhibitor [EPC] PDE4 2014-01-01
Crisaborole Vehicle Crisaborole Vehicle Pfizer marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
Apremilast (CC-10004) Apremilast (CC-10004) Virginia Clinical Research, Inc. marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
Crisaborole ointment, 2% Crisaborole ointment, 2% Pfizer marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
LASW1835 LASW1835 Almirall, S.A. phase 3 PDE4 inhibitor PDE4
BPN14770/ zatolmilast BPN14770/ zatolmilast Tetra Discovery Partners phase 3 Phosphodiesterase 4D (PDE4D) inhibitor PDE4D

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE4 inhibitor class)

  1. GlaxoSmithKline · 7 drugs in this class
  2. Almirall, S.A. · 4 drugs in this class
  3. Pfizer · 3 drugs in this class
  4. Dr. Reddy's Laboratories Limited · 1 drug in this class
  5. Galderma R&D · 1 drug in this class
  6. Handok Inc. · 1 drug in this class
  7. R-Pharm · 1 drug in this class
  8. Advenchen Pharmaceuticals, LLC. · 1 drug in this class
  9. Shaanxi Micot Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apremilast Modified Release 13 — Competitive Intelligence Brief. https://druglandscape.com/ci/apremilast-modified-release-13. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: